Selinexor PK. (A) Selinexor plasma concentration in patients with AML as a function of time over 48 hours for doses as listed administered on day 1. Points are means and standard error for the number of patients at each dose listed in parentheses on the graph. Median in vitro IC₅₀ is 86.4 ng/mL (or 195 nM). (B) C_max, AUC_{0-8 h}, and AUC_{0-48 h} were different across doses with high statistical significance (P < .0001 by ANOVA).